VAXELIS susp inj avec 1 aiguille 10 ser pré 0.5 ml

7680669400033 CH-66940 J07CA09 08.08.

Reimbursement limitations:

0808 NEU

La prise en charge des coûts des vaccins au titre de mesure préventive dans le …

VAXELIS susp inj avec 1 aiguille 10 ser pré 0.5 ml
VAXELIS susp inj avec 1 aiguille 10 ser pré 0.5 ml
VAXELIS susp inj avec 1 aiguille 10 ser pré 0.5 ml
1 / 3
google

Details

Product number
6694001
CPT
-
Packaging group
10
Unit
Fertigspritze(n)
Composition
polysaccharida haemophili influenzae typus B conjugata cum proteino neisseriae meningitidis B 53 µg corresp. polysaccharida haemophili influenzae typus B 3 µg et neisseria meningitidis B outer membrane protein complex 50 µg, hepatitidis B viri antigenum ADNr 10 µg, toxoidum pertussis 20 µg, haemagglutininum filamentosum 20 µg, pertactinum 3 µg, fimbriae Typ 2 und 3 5 µg, toxoidum diphtheriae min. 20 U.I., toxoidum tetani min. 40 U.I., virus poliomyelitis typus 1 inactivatus (Mahoney) 40 U., virus poliomyelitis typus 2 inactivatus (MEF-1) 8 U., virus poliomyelitis typus 3 inactivatus (Saukett) 32 U., aluminium ut aluminii phosphas et aluminii hydroxyphosphas sulfas amorphus, natrii phosphates, acidum hydrochloridum q.s. ad pH, natrii hydroxidum q.s. ad pH, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.95 mg, residui: glutaralum, formaldehydum, neomycinum, streptomycinum, polymyxinum B, albuminum seri bovis, aluminii thiocyanas, faecis proteina.

Articles (1)

Vaxelis 0.5 ml, Injektionssuspension
Injektionssuspension
10
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
17/06/2024
Professional SmPC
Français
17/06/2024
Professional SmPC
Italien
17/06/2024

Detailed composition

Substance Quantity Type Category
(N/A)
53.0 UG Substance Wirkstoff (Principe actif)
(N/A)
3.0 UG Substance WIIS
(N/A)
50.0 UG Substance WIIS
(N/A)
10.0 UG Substance Wirkstoff (Principe actif)
(N/A)
20.0 UG Substance Wirkstoff (Principe actif)
(N/A)
20.0 UG Substance Wirkstoff (Principe actif)
(N/A)
3.0 UG Substance Wirkstoff (Principe actif)
(N/A)
5.0 UG Substance Wirkstoff (Principe actif)
(N/A)
- Substance Wirkstoff (Principe actif)
(N/A)
- Substance Wirkstoff (Principe actif)
(N/A)
40.0 U Substance Wirkstoff (Principe actif)
(N/A)
8.0 U Substance Wirkstoff (Principe actif)
(N/A)
32.0 U Substance Wirkstoff (Principe actif)
(N/A)
- Substance HIMDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
1.95 MG Substance HBESI
(N/A)
- Substance RESI
(N/A)
- Substance RESI
(N/A)
- Substance RESI
(N/A)
- Substance RESI
(N/A)
- Substance RESI
(N/A)
- Substance RESI
(N/A)
- Substance RESI
(N/A)
- Substance RESI

Authorization holder

Future Health Pharma GmbH

8620 Wetzikon ZH

Authorization information

Swissmedic authorization number
66940
Drug name
Vaxelis, Injektionssuspension
Galenic form
SUPA
ATC Code
J07CA09
Authorization status
Z
Dispensation category
B
First authorization
28/08/2019
Authorization expiration date
31/12/9999
IT number
08.08.
Domain
Human medicine
Field of application
Grundimmunisierung und Auffrischimpfung bei Säuglingen und Kleinkindern ab einem Alter von 6 Wochen bis 4 Jahre (vor dem 5. Geburtstag) gegen Diphtherie, Tetanus, Pertussis, Hepatitis B, Poliomyelitis und durch Haemophilus influenzae Typ b (Hib) verursachte invasive Krankheiten.

Packaging details

Description (FR)
VAXELIS susp inj avec 1 aiguille 10 ser pré 0.5 ml
Description (DE)
VAXELIS Inj Susp mit 1 Nadel 10 Fertspr 0.5 ml
Market launch
28/08/2019
Narcotic (BTM)
No

Other packaging sizes

VAXELIS susp inj av 2 aiguilles ser pré 0.5 ml
1 FESP
View
VAXELIS susp inj av 2 aiguilles 10 ser pré 0.5 ml
10 FESP
View